Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Combivent MDI is a **combination inhalation aerosol** containing two active ingredients: **ipratropium bromide** (an anticholinergic bronchodilator or short-acting muscarinic antagonist) and **albuterol sulfate** (a short-acting beta2-adrenergic agonist). This metered dose inhaler delivers both drugs simultaneously to the airways for the **maintenance treatment of bronchospasm in patients with chronic obstructive pulmonary disease (COPD)** who require a second bronchodilator. Ipratropium works by blocking muscarinic receptors, preventing bronchoconstriction triggered by acetylcholine, while albuterol relaxes bronchial smooth muscle through stimulation of beta2-adrenergic receptors, promoting bronchodilation. Each actuation delivers 18 mcg ipratropium bromide and 103 mcg albuterol sulfate from the mouthpiece.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on combivent mdi.